Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women-Reference-Cited by-同舟云学术

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Published:2009-07 Issue:9686 Volume:374 Page:301-314
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Paavonen J,Naud P,Salmerón J,Wheeler CM,Chow S-N,Apter D,Kitchener H,Castellsague X,Teixeira JC,Skinner SR,Hedrick J,Jaisamrarn U,Limson G,Garland S,Szarewski A,Romanowski B,Aoki FY,Schwarz TF,Poppe WAJ,Bosch FX,Jenkins D,Hardt K,Zahaf T,Descamps D,Struyf F,Lehtinen M,Dubin G

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. Age considerations when vaccinating against HPV;Wright;Gynecol Oncol,2008

2. Enhanced humoral and memory B cell immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only;Giannini;Vaccine,2006

3. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial;Paavonen;Lancet,2007

4. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial;Harper;Lancet,2004

5. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial;Harper;Lancet,2006

Cited by 1355 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects?;Vaccine;2024-10

2. Our Daughters—Ourselves: Evaluating the Impact of Paired Cervical Cancer Screening of Mothers with HPV Vaccination for Daughters to Improve HPV Vaccine Coverage in Bamako, Mali;Vaccines;2024-09-06

3. Time-resolved fluorescence (TRF) for total IgG and HPV16-specific antibody detection in first-void urine and serum: A comparative study;Journal of Virological Methods;2024-09

4. Optimal human papillomavirus vaccination strategies in the context of vaccine supply constraints in 100 countries;eClinicalMedicine;2024-08

5. Knockdown of YTHDF2 initiates ERS-induced apoptosis and cancer stemness suppression by sustaining GLI2 stability in cervical cancer;Translational Oncology;2024-08